Physician profile
Ralph Rothenberg
NPI 1548266190
$5,477.79
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,501 · 2020: $449 · 2021: $702 · 2022: $1,399 · 2023: $427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $427.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $427.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $846.17 | 2019-2023 | Enbrel, Otezla, Tavneos |
| Janssen Biotech, INC. | $630.35 | 2019-2023 | Tremfya, Remicade, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $507.05 | 2019-2023 | |
| Abbvie INC. | $485.38 | 2019-2023 | Rinvoq, Skyrizi |
| Ucb, INC. | $414.81 | 2019-2023 | Cimzia |
| Pfizer INC. | $303.05 | 2019-2023 | |
| Lilly USA, LLC | $295.48 | 2019-2023 | Taltz |
| Glaxosmithkline, LLC. | $259.75 | 2019-2022 | |
| Genentech USA, INC. | $258.69 | 2019-2023 | Actemra |
| Mallinckrodt Hospital Products INC. | $240.26 | 2020-2023 | Acthar |
| Mallinckrodt Enterprises LLC | $197.07 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $158.69 | 2020-2023 | Opsumit |
| E.R. Squibb & Sons, L.L.C. | $150.48 | 2019-2023 | Orencia |
| Aurinia Pharma U.S., INC. | $133.20 | 2021-2023 | Lupkynis |
| Regeneron Healthcare Solutions, INC. | $109.67 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $99.41 | 2021-2022 | |
| Hikma Pharmaceuticals USA | $77.65 | 2019 | |
| Horizon Therapeutics Plc | $69.24 | 2019-2023 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.40 | 2019-2023 | Ofev |
| Celgene Corporation | $34.49 | 2019 | |
| Kiniksa Pharmaceuticals, Ltd. | $33.82 | 2021-2023 | Arcalyst |
| Ultragenyx Pharmaceutical INC. | $29.15 | 2021-2022 | |
| Sobi, INC | $26.85 | 2021-2022 | |
| Sebela Pharmaceuticals INC. | $20.43 | 2019 | |
| Daiichi Sankyo INC. | $18.17 | 2019 | |
| Merck Sharp & Dohme LLC | $17.58 | 2019 | |
| Medexus Pharma, INC. | $12.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ralph Rothenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.